Indolyl-3-glyoxylic acid derivatives having antitumor action
    2.
    发明授权
    Indolyl-3-glyoxylic acid derivatives having antitumor action 失效
    具有抗肿瘤作用的吲哚基-3-乙醛酸衍生物

    公开(公告)号:US07579365B2

    公开(公告)日:2009-08-25

    申请号:US10309204

    申请日:2002-12-04

    IPC分类号: A61K31/44 C07D401/00

    摘要: The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agents and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.

    摘要翻译: 本发明涉及通式I的N-取代的吲哚-3-乙醛酰胺作为抗肿瘤剂和具有抗肿瘤作用的药物组合物的用途,其特征在于其含有至少一种通式1的化合物,如果 也适用于生理上可耐受的酸加成盐或N-氧化物的形式。 此外,本发明还包括抗肿瘤剂,其包含根据通式1的一种或多种N-取代的吲哚-3-乙醛酰胺作为活性化合物,以及如果合适的话,其生理上可耐受的酸加成盐,以及如果可能的话,N-氧化物和 片剂,包衣片剂,胶囊,输注溶液或安瓿,栓剂,贴剂,可通过吸入,悬浮液,霜剂和软膏使用的粉末制剂的药学上可用的载体和/或稀释剂或辅助物质。

    1,3,5-tribsubstituted indazole derivatives, processes for preparing, and
for pharmacological treatment therewith
    10.
    发明授权
    1,3,5-tribsubstituted indazole derivatives, processes for preparing, and for pharmacological treatment therewith 失效
    1,3,5-三取代吲唑衍生物,制备方法和用于药物治疗

    公开(公告)号:US5776932A

    公开(公告)日:1998-07-07

    申请号:US821740

    申请日:1997-03-20

    摘要: 1,3,5-trisubstituted indazole derivatives of the formula ##STR1## wherein R1 is H, (b) a C.sub.1-6 straight or branched, substituted or unsubstituted alkyl residue, (c) a C.sub.3-7 cycloalkyl residue, (d) an unsustituted or substituted phenyl, naphthyl, anthranyl, or fluorenyl residue, (e) a quinolin-2-ylmethoxy, or pyridin-2-ylmethoxy residue; X is O, or a --NH, --NH--(C.dbd.O)--NH--, --NH--(C.dbd.O)--O--, --NH--(C.dbd.O)--, or --NH--CH.sub.2 --(C.dbd.O)-- residue; Y is O, or S; R.sub.2 is H; Z is a SO, SO.sub.2, --(CH.sub.2).sub.p --, --(CH.sub.2).sub.p --O--, --O--(CH.sub.2).sub.p --, --(CH.sub.2).sub.p --(C.dbd.O)--, --(C.dbd.O)--(CH.sub.2).sub.p --, --(CH.sub.2).sub.p --(C.dbd.O)--NH--, --NH--(C.dbd.O)--(CH.sub.2).sub.p --, --(CH.sub.2).sub.p --CHOH--, --CHOH--(CH.sub.2).sub.p --, --(CH.sub.2).sub.p --CH.dbd.CH--, or --CH.dbd.CH--(CH.sub.2).sub.p -- residue, wherein p is between 1 and 6; A is a phenyl, naphthyl, anthranyl, fluorenyl, thiophenyl, pyridinyl, isoxazolyl, benzimidazolyl, benz�1,3!dioxolyl, pyrimidyl, pyrimidine-2,4-dionyl, quinolinyl, quinoxazolinyl, morpholinyl, or pyrrolidinyl residue; and, R.sub.3, R.sub.4, and R.sub.5, the same or different, are defined in the specification; and pharmaceutically acceptable salts, stereoisomers, racemates, racemic modifications, and enantiomers thereof. The invention also relates to specific compounds, processes for preparing and for treating an allergic, asthmatic, inflamed condition of a host, or for modulating the immune system of a host.

    摘要翻译: 式(I)的1,3,5-三取代吲唑衍生物其中R 1是H,(b)C 1-6直链或支链,取代或未取代的烷基残基,(c)C 3-7环烷基残基, (d)未取代或取代的苯基,萘基,蒽基或芴基残基,(e)喹啉-2-基甲氧基或吡啶-2-基甲氧基残基; X是O,或-NH,-NH-(C = O)-NH-,-NH-(C = O)-O-,-NH-(C = O) - 或-NH-CH 2 - C = O) - 残基; Y是O或S; R2为H; Z是SO,SO 2, - (CH 2)p - , - (CH 2)p O-,-O-(CH 2)p - , - (CH 2)p - (C = O) - , - (C = O) (CH2)p-, - (CH2)p-(C = O)-NH-,-NH-(C = O) - (CH2)p-, - (CH2)p-CHOH-,-CHOH-(CH2 )对 - , - (CH 2)p -CH = CH-或-CH = CH-(CH 2)p - 残基,其中p为1至6; A是苯基,萘基,蒽基,芴基,噻吩基,吡啶基,异恶唑基,苯并咪唑基,苯并[1,3]二氧杂环戊烯基,嘧啶基,嘧啶-2,4-二酰基,喹啉基,喹唑啉基,吗啉基或吡咯烷基残基; 和R3,R4和R5相同或不同,在本说明书中定义; 和其药学上可接受的盐,立体异构体,外消旋体,外消旋体和其对映异构体。 本发明还涉及具体化合物,用于制备和治疗宿主的过敏性,哮喘,发炎状况或调节宿主免疫系统的方法。